Ampio receives patent in USA related to autologous or allogenic stem cells
Ampio Pharmaceuticals announced the allowance of an important composition and methods patent in the USA complimenting a series of patents on Ampion. The patent is entitled: "COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION, AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME." The patent includes 34 allowed claims. Autologous or allogenic stem cells are used in clinical practice, including for osteoarthritis of the knee. Ampion has demonstrated in vitro effects on mesenchymal stem cells on recruitment and differentiation. This process occurs naturally in the body, however, to augment the number of stem cells that would survive after injection in the body and their differentiation into tissue specific cells, incubating them with Ampion prior to injection is the subject of this patent.